Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
about
Clinical trials in severe sepsis with drotrecogin alfa (activated)Recombinant human activated protein C for severe sepsis in neonatesHuman recombinant activated protein C for severe sepsisHuman recombinant protein C for severe sepsis and septic shock in adult and paediatric patientsHuman recombinant activated protein C for severe sepsisHuman recombinant activated protein C for severe sepsisUse of human protein C concentrates in the treatment of patients with severe congenital protein C deficiencySurviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008Advances in the management of sepsis and the understanding of key immunologic defectsPAMPs and DAMPs as triggers for DICInitial resuscitation and management of pediatric septic shockDynamic Computational Model of Symptomatic Bacteremia to Inform Bacterial Separation Treatment RequirementsSepsis: in search of cure.Research as a Standard of Care in the PICU.Coinfection with Staphylococcus aureus increases risk of severe coagulopathy in critically ill children with influenza A (H1N1) virus infection.Biomarker discovery and development in pediatric critical care medicine.Identification of pediatric septic shock subclasses based on genome-wide expression profiling.The pediatric sepsis biomarker risk model.A recombinant fragment of von Willebrand factor reduces fibrin-rich microthrombi formation in mice with endotoxemiaExisting data analysis in pediatric critical care researchWhy are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis.Practical aspects of treatment with drotrecogin alfa (activated)New parenteral anticoagulants in development.A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials.A simple meningococcal sepsis prognostic score: focusing on the human animalActivated protein C action in inflammationInhaled activated protein C protects mice from ventilator-induced lung injury.Update on pediatric sepsis: a review.Role of innate host defenses in susceptibility to early-onset neonatal sepsis.The host response to sepsis and developmental impactNo child left behind: Enrolling children and adults simultaneously in critical care randomized trialsThe role of angiogenic factors in predicting clinical outcome in severe bacterial infection in Malawian children.The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats.Leukocyte subset-derived genomewide expression profiles in pediatric septic shockInter-alpha inhibitor protein administration improves survival from neonatal sepsis in miceHuman protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patientsA phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome.Introduction to Pediatric Sepsis.Results from the National Sepsis Practice Survey: use of drotrecogin α (activated) and other therapeutic decisions.Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.
P2860
Q21195024-0E846B7E-1FB9-4A11-A4BE-2900AB741DBBQ24200439-68E4BAB0-B890-4DA1-95E9-C9522948CEC8Q24201123-67A05EAA-0813-4EFD-9DB7-3259BA0275C3Q24202128-F8AEBCB9-9E5A-4EAF-9AD9-2A4C7EBAF389Q24235181-BA38D11C-8704-46B1-A9C8-6E5556DB14A4Q24242859-49F9183F-CC06-4F5F-9A0C-E469D3A34D93Q24612253-23E2D7C7-09BA-48F0-BF69-C8C8B9865298Q24644984-A5A3D996-4571-415A-86D3-703CC600DDA7Q26865386-33964D38-5D56-4AAE-ADA1-EA549480549EQ27013790-34AF818E-AC86-4DAF-8734-DAC0A6C21524Q28083003-B8329728-142B-4310-8B7A-B0580A406029Q28554305-7C5EC784-5A7B-4F74-A91D-3EAECA1BED13Q30251753-28A304E6-C297-4A12-B476-3BB17986853AQ30278453-004DE793-4E10-473E-B958-9CCD2E0F29C1Q30421191-A6E6226E-2D2C-4790-BD41-5DD5BEBD7677Q30428168-8AD31ACE-6EC7-493B-AE20-0397F7A22ACEQ30438982-77B9333E-1C8A-4599-AAA9-5DF169D83EFCQ30540641-852FB1FC-AFDD-41C9-AA02-2A78B3ED05FFQ30836660-2B84E93A-8C6B-42BD-9280-B7BE6C78F032Q30842575-5ADAA8D7-21D3-4747-9181-A6B2EC208441Q33338424-D43A9838-A044-4058-93DF-26E8F91D86E4Q33378616-3F3C7061-A12D-4A4A-AD74-F90D984CB990Q33392647-45C06C63-051B-4983-842E-56A9B6915CA1Q33517961-75958180-7C45-4326-B168-415F70FDF3ACQ33752719-275B6B72-4D10-48DC-BE9F-D4C29F8A86AEQ33846825-572A8EE2-FB7B-49B1-B129-7D2C7436DFAAQ33919295-41B691D1-9B4F-46FA-80E8-B4A427B7238FQ33919446-F7D35712-CD7A-4C4C-BF30-79EF5E224EA1Q33940417-A9DE5792-FA3E-400B-8DE2-8EB233C804FEQ33950741-C084C9F1-16DF-4795-9114-00293F0967D1Q33992275-5A183061-D404-430A-831F-213F790121BBQ34026872-4C829F8F-67A2-44BF-9E0C-042CF0794D66Q34053131-87F816FA-B2C3-426F-A892-33D74F7F19BDQ34082462-C5DFF98C-2FDF-4B6B-B547-D9E3E2CC32F8Q34084719-1454D893-5242-467E-A502-058900D94883Q34153375-81E6EBF3-637F-446C-95F3-60B7C9792382Q34160584-90991DFF-E242-4A09-A98F-2DF036FDD696Q34280113-D3238759-90CB-42A2-9D6D-55732E18A4E7Q34297740-5FD6A8B9-D26D-4973-B3A7-95941F6267BBQ34370297-9955CF6E-4E56-4DB5-B52C-918DE3118D69
P2860
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Drotrecogin alfa (activated) i ...... I randomised controlled trial.
@en
type
label
Drotrecogin alfa (activated) i ...... I randomised controlled trial.
@en
prefLabel
Drotrecogin alfa (activated) i ...... I randomised controlled trial.
@en
P2093
P921
P1433
P1476
Drotrecogin alfa (activated) i ...... II randomised controlled trial
@en
P2093
Brahm Goldstein
Brett Giroir
David P Sundin
Dazhe Wang
Heidi Dalton
Howard Levy
Mark D Williams
REsearching severe Sepsis and ...... spective (RESOLVE) study group
Robinette Angle
Shamel A Abd-Allah
P304
P356
10.1016/S0140-6736(07)60411-5
P407
P577
2007-03-01T00:00:00Z